In the last trading session, 2.21 million Adc Therapeutics SA (NYSE:ADCT) shares changed hands as the company’s beta touched 1.92. With the company’s per share price at $2.71 changed hands at $0.01 or 0.37% during last session, the market valuation stood at $268.77M. ADCT’s last price was a discount, traded about -52.4% off its 52-week high of $4.13. The share price had its 52-week low at $1.05, which suggests the last value was 61.25% up since then. When we look at Adc Therapeutics SA’s average trading volume, we note the 10-day average is 1.18 million shares, with the 3-month average coming to 624.37K.
Analysts gave the Adc Therapeutics SA (ADCT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended ADCT as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight.
Adc Therapeutics SA (NYSE:ADCT) trade information
Instantly ADCT was in green as seen at the end of in last trading. With action -2.17%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 6.27%, with the 5-day performance at -2.17% in the red. However, in the 30-day time frame, Adc Therapeutics SA (NYSE:ADCT) is 2.26% up. Looking at the short shares, we see there were 4.53 million shares sold at short interest cover period of 4.89 days.
The consensus price target for the stock as assigned by Wall Street analysts is 8, meaning bulls need an upside of 66.12% from its current market value. According to analyst projections, ADCT’s forecast low is 7 with 13 as the target high. To hit the forecast high, the stock’s price needs a -379.7% plunge from its current level, while the stock would need to soar -158.3% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 1.38%. The 2025 estimates are for Adc Therapeutics SA earnings to increase by 7.41%, but the outlook for the next 5-year period is at 16.36% per year.
ADCT Dividends
Adc Therapeutics SA is expected to release its next quarterly earnings report on 2025-May-14.
Adc Therapeutics SA (NYSE:ADCT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 21.59% of Adc Therapeutics SA shares while 67.58% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 86.19%. There are 67.58% institutions holding the Adc Therapeutics SA stock share, with REDMILE GROUP, LLC the top institutional holder. As of 2024-06-30, the company held 15.9568% of the shares, roughly 15.27 million ADCT shares worth $48.25 million.
PROSIGHT MANAGEMENT, LP holds the second largest percentage of outstanding shares, with 10.0009% or 9.57 million shares worth $30.24 million as of 2024-06-30.
